glp-1 market news november 2025 ISPOR 2025: Exploring reasons for discontinuation Canada GLP-1 Agonists Weight Loss

Over the years, researchers have followed this drug to see who it harms in certain organ systems and haven't seen any significant red flags in the heart or blood vessels [7]

Available from: World Health Organization

And, most recently, an analysis of the electronic health records of 817,309 patients with a history of AUD from January 2014 to August 2022 found that those taking GLP-1s experienced lower rates of alcohol intoxication

Clinical trial data and post-marketing surveillance indicate that gastrointestinal adverse effects are among the most frequent reasons for treatment discontinuation

Shares of Gland Pharma Ltd ended at 1,498.50, up by 14.35, or 0.97%, on the BSE